FDA Regulation of Cosmetic Products  

Cosmetics are a part of daily life for millions of people—but what many consumers and businesses don’t realize is that cosmetic products are regulated by the U.S. Food and Drug Administration (FDA). While cosmetics do not require FDA approval before going to market, they must be safe for use, properly labeled, and free from misleading claims. 

This page provides a clear overview of how the FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the distinctions between cosmetics and drugs, and the responsibilities of manufacturers and distributors. Whether you’re a consumer, formulator, or importer, understanding these regulatory requirements is essential to ensure compliance and protect public health. 

Definition of a Cosmetic (Per FD&C Act, Sec. 201(i)) 

The FDA defines a cosmetic as: 

“Articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body… for cleansing, beautifying, promoting attractiveness, or altering the appearance.” 

This includes: 

  • Skin moisturizers 
  • Perfumes and colognes 
  • Lipsticks and nail polishes 
  • Makeup (foundation, eyeshadow, etc.) 
  • Shampoos, conditioners 
  • Deodorants (but not antiperspirants—those are drugs) 

NOT included: Products that are intended to treat or prevent disease or affect the structure/function of the body – these are drugs, even if they are applied topically. 

Key Regulatory Features 

  1. Pre-market Approval
  • No FDA premarket approval is required for most cosmetics. 
  • Exception: Color additives (e.g., dyes used in eye makeup) must be FDA-approved for their specific use. 
  1. Labeling
  • Must comply with 21 CFR Part 701 (labeling) and 740 (warning statements). 
  • Requires: 
  • Identity of the product 
  • Net contents 
  • Ingredient declaration (descending order) 
  • Manufacturer/distributor info 
  • Any necessary warnings 
  1. Good Manufacturing Practice (GMP)
  • Unlike drugs, there are no mandatory GMP regulations for cosmetics—but the FDA recommends following voluntary GMP guidelines to ensure safety and quality. 
  1. Adverse Event Reporting (MoCRA Update, 2022)

The Modernization of Cosmetics Regulation Act (MoCRA) now requires: 

  • Serious adverse event reporting (as of December 2023) 
  • Facility registration and product listing (with FDA, beginning July 2024) 
  • Safety substantiation: Companies must maintain documentation that products are safe under labeled conditions of use 
  1. Identification and Listing
  • Product listing and facility registration are voluntary (historically) but become mandatory under MoCRA. 
  • No National Drug Code (NDC) or formal registration number is required (unlike drugs). 

Key Distinctions: 

Feature 

OTC Drug 

Cosmetic 

Primary Purpose 

Treat or prevent disease, or affect body function 

Cleanse, beautify, or alter appearance 

FDA Premarket Approval 

Required (for NDA); not for monographs 

Not required (except color additives) 

GMP 

Mandatory (21 CFR 210/211) 

Voluntary (but encouraged) 

Labeling Requirements 

Strict (Drug Facts panel) 

Identity, contents, warnings 

Adverse Event Reporting 

Required 

Required under MoCRA 

International Notes 

  • EU: Cosmetics are highly regulated under Regulation (EC) No. 1223/2009. Products must have a Responsible Person, undergo a safety assessment, and be registered in the CPNP database. 
  • Canada: Regulated by Health Canada; require Cosmetic Notification Form, proper labeling, and safety substantiation. 
  • Japan and ASEAN countries have similar frameworks with strict labeling and ingredient restrictions. 

 

colorful array of FDA-regulated cosmetics

FDA Issues Warning on Counterfeit Botox Products 

Real Botox PackagingReal Botox Cosmetic PackagingReal Botox PackagingCounterfeit Botox Products  The U.S. Food and Drug Administration (FDA) has issued a critical alert concerning the presence of counterfeit Botox products in various states, posing severe risks to...

read more

FDA Approves XACT Carotid Stent System

A Breakthrough for Stroke Prevention  Abbott Vascular Inc. has received FDA approval for its groundbreaking XACT Carotid Stent System, a significant advancement in stroke prevention technology. Approved on February 7, 2024, this innovative system offers new hope for...

read more

FDA Approves Xolremdi for WHIM Syndrome 

A Breakthrough for Rare Infections  In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted approval for Xolremdi (mavorixafor) capsules, marking a significant milestone in the treatment of WHIM syndrome. Let's delve into what this...

read more